Todos Medical Ltd. (OTCQB: TOMDF) announced earlier this week the "publication of data from a human clinical study in the scientific journal Analytical Chemistry entitled 'Differential Diagnosis of the Etiologies of Bacterial and Viral Infections Using Infrared Microscopy of Peripheral Human Blood Samples and Multivariate Analysis'. The data demonstrate that the use of the Fourier-transform infrared (FTIR) spectroscopy technique on peripheral blood samples yields a differential diagnosis when seeking to make a clinical diagnosis between patients with viral infections, bacterial infections and healthy controls.
'With the recent explosion of novel coronavirus (2019-nCoV) worldwide, definitively diagnosing viral infections versus bacterial or other types of infections that present with similar symptoms has become paramount in order to appropriately triage patients and guide treatment decisions for healthcare professionals,' said Gerald Commissiong, President & CEO of Todos Medical.
'Todos' proprietary FTIR blood testing platform that focuses on the immune system's reaction to cancer has received CE Marks in Europe for the diagnosis of breast cancer and colon cancer, has recently achieved strong analytical performance results from our proprietary sample preparation methods, and is currently enrolling a pre-commercial breast cancer study in Romania with distribution partner Orot+ (a division of Orot Luces) ahead of an expected commercial launch in Romania later this year.
Based on these recent successes and this publication from the Company's licensors at Ben Gurion University, we have now formally begun to evaluate the commercial feasibility of applying our technology towards the diagnosis of bacterial and viral infections, including coronavirus.
............
[DUFU] Notice of Interest of Substantial Shareholders - EASTSPRING INVESTMENTS BERHAD on 03-Apr-2020
Total no of securities after change Direct (units) 12,898,620 Direct (%) 5.03
• Spectrometers that are used in pure research or high-end applications in academia or large corporations. These instruments perform sophisticated tasks such as IR imaging of cells, or biopsies and inspections of semiconductors. Depending on the bells and whistles, these instruments can cost more than $100,000.
cashless payment is the future. all developed countries carry little to no cash. what's holding you back? waiting for a lower price of a few cents ans risking missing the boat altogether?
agree with stephen88. Though i love this counter, i am holding some. But, I would like to go in more when it is corrected as we know: 1. shops are closed in these few weeks means less use of EDC and therefore ETP less 2. no tourists from China and other countries to help to boost the consumption, so ETP down again
However, I may want to highlight that Revenue still has its own advantage here: 1. Online shopping like lazada and others are still active 2. EDC supplies are readily there even before MCO kicked in
So, let's wait for the correction, or QR if you want to wait longer.
Just a 2 cents from me. You may decide the buy call your own. Just remember keep for long term. Keep the capital once there is some losses.
Reiko, whenever you are not sure, it is always wise to space out your purchases. You can never buy at the lowest point because nobody can predict when the lowest point is. For example, if you have rm10k, split your money to batches of RM 2-3k, then observe the share price movement. Of course, if you are fully confident in the company, then you should just whack RM 10k, for example last month when REV dropped to 0.7x, which is totally unreasonable for a company with record breaking high profit every year. Before covid crash, revenue was around 1.3, so for the short term I would say upside limited because there's a resistance there. But in the long term? Revenue is the future of e payment systems! A Revolutionary company. I'm confident that it can still rise by 100+%. It has already risen by more than 200% since 2018!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
MonkeyFoo
265 posts
Posted by MonkeyFoo > 2020-04-03 12:05 | Report Abuse
国家银行预测,大马今年国内生产总值成长最严重将下挫到-2.0%,而最佳状况也只有0.5%。
================
订阅 #当今大马,支持独立媒体!
http://subscription.malaysiakini.com/cn
OMG